Vaxcyte, Inc. Stock Price, News & Analysis

Vaxcyte, Inc. (Nasdaq: PCVX) announced its Q2 2021 financial results, reporting a net loss of $23.7 million, up from $20.3 million in Q2 2020. As of June 30, 2021, cash and investments stood at $341.0 million, down from $386.2 million at the end of 2020. The company is advancing its lead pneumococcal vaccine candidate, VAX-24, and is on track for an IND application submission between January and June 2022. Vaxcyte also secured an additional $3.2 million from CARB-X for VAX-A1, a vaccine targeting Strep infections. Operational expenses saw R&D at $17.7 million and G&A at $6.1 million.

Vaxcyte, Inc. (Nasdaq: PCVX) announced an additional $3.2 million grant from CARB-X, bringing total potential funding to $29.7 million for the development of its vaccine candidate, VAX-A1. This funding aims to enable the Investigational New Drug (IND) application for VAX-A1, a vaccine targeting Group A Streptococcus, which causes 700 million cases of illness annually. The vaccine is critical in addressing antibiotic resistance and reducing morbidity and mortality related to this widespread infection.

Vaxcyte, Inc. (Nasdaq: PCVX), a company focused on next-generation vaccines, will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 4:00 PM ET. The event aims to showcase its innovative vaccine solutions designed to combat severe infectious diseases.

The presentation will be accessible via the company’s website, with a replay available for 30 days. Vaxcyte is known for its advanced cell-free protein synthesis platform and its lead candidate, VAX-24, targeting invasive pneumococcal disease.

Vaxcyte, Inc. (Nasdaq: PCVX) reported Q1 2021 financial results and updates on its vaccine pipeline. As of March 31, 2021, it had $370.9 million in cash. R&D expenses decreased to $17.3 million, while G&A expenses rose to $5.9 million, resulting in a net loss of $21.2 million. The company is progressing with its 24-valent pneumococcal vaccine, VAX-24, aiming to submit an IND application to the FDA by mid-2022. Vaxcyte also appointed Janet Graesser as Vice President of Corporate Communications, enhancing its strategic communications.

Vaxcyte announced the publication of preclinical data for its investigational VAX-24 vaccine in Vaccine, showing that all 24-valent serotypes in VAX-24 elicited robust immune responses compared to existing vaccines. This 24-valent pneumococcal conjugate vaccine targets strains not covered by the current 13-valent vaccine, addressing a significant unmet medical need in preventing invasive pneumococcal disease. Vaxcyte plans to submit an Investigational New Drug application to the FDA for VAX-24, advancing towards clinical trials.

Vaxcyte, Inc. (Nasdaq: PCVX) announced its participation in the BofA Securities 2021 Health Care Conference set for May 13, 2021, at 3:30 PM ET. The event will feature company management presenting the latest developments in their innovative vaccines aimed at combating infectious diseases. A live webcast will be accessible via their official website, with a replay available for 30 days post-conference. Vaxcyte is noted for its advanced vaccine candidates including VAX-24, addressing pneumococcal disease, and VAX-XP for broader strain coverage.

Vaxcyte, Inc. (Nasdaq: PCVX) announced its participation in the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 1:30 p.m. ET. The event aims to showcase Vaxcyte's innovative vaccine development efforts, including its lead candidate, VAX-24, a preclinical pneumococcal conjugate vaccine designed for preventing invasive pneumococcal disease. A live webcast will be available through the company's website, with a replay offered for 30 days post-conference. Vaxcyte is focused on creating novel vaccines to address common infectious diseases globally.

Vaxcyte, Inc. (Nasdaq: PCVX) reported its financial results for Q4 and full year 2020, highlighting a net loss of $20.7 million for Q4 and $89.2 million for the year. The company announced a revised timeline for its VAX-24 IND application submission, now expected between January and June 2022, due to manufacturing constraints. Key advancements included new immunogenicity data for its VAX-XP program and the final candidate nomination for VAX-A1. Vaxcyte's cash position increased to $386.2 million, supported by its IPO and Series D financing in 2020.

Vaxcyte, Inc. (Nasdaq: PCVX) will report its financial results for Q4 and the full year 2020 after market close on March 29, 2021. A conference call is scheduled for 4:30 p.m. ET to discuss the results and provide a business update. Vaxcyte develops innovative vaccines aimed at preventing major infectious diseases, leveraging its cell-free protein synthesis platform, XpressCF. The lead candidate, VAX-24, is a preclinical 24-valent pneumococcal conjugate vaccine. Additional candidates include VAX-XP, VAX-A1, and VAX-PG.